Clinical trials
Phase 2 Prostatic Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 11 |
| 2025 | 7 |
| 2026 | 11 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 20 |
| Unknown status | 13 |
| Not yet recruiting | 11 |
| Active, not recruiting | 4 |
| Completed | 3 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 8 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 7 |
| Sun Yat-sen University | 4 |
| Astellas Pharma Global Development, Inc. | 2 |
| First Affiliated Hospital of Fujian Medical University | 2 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| Peking University First Hospital | 2 |
| baotai Liang | 2 |
| Bayer | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 52 |
| Breast Neoplasms | 4 |
| Adenocarcinoma | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colorectal Neoplasms | 3 |
| Endometrial Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Melanoma | 2 |
| Stomach Neoplasms | 2 |
| Uterine Cervical Neoplasms | 2 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.